JP2016116527A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016116527A5 JP2016116527A5 JP2016023490A JP2016023490A JP2016116527A5 JP 2016116527 A5 JP2016116527 A5 JP 2016116527A5 JP 2016023490 A JP2016023490 A JP 2016023490A JP 2016023490 A JP2016023490 A JP 2016023490A JP 2016116527 A5 JP2016116527 A5 JP 2016116527A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- treatment
- mammalian
- fibrosis
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000004965 antibodies Human genes 0.000 claims 6
- 108090001123 antibodies Proteins 0.000 claims 6
- 102100015399 CDH11 Human genes 0.000 claims 2
- 206010016654 Fibrosis Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000004761 fibrosis Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 108010000953 osteoblast cadherin Proteins 0.000 claims 2
Claims (2)
- 線維症の治療を必要とする哺乳動物被験体における線維症の治療のための医薬の製造におけるヒト化抗体の使用であって、該抗体は、哺乳動物カドヘリン−１１タンパク質のＥＣ１ドメインに特異的に結合し、配列番号：６９を含む抗体重鎖可変領域を含む、使用。
- 癌の治療を必要とする哺乳動物被験体における癌の治療のための医薬の製造におけるヒト化抗体の使用であって、該抗体は、哺乳動物カドヘリン−１１タンパク質のＥＣ１ドメインに特異的に結合し、配列番号：６９を含む抗体重鎖可変領域を含む、使用。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36469810P | 2010-07-15 | 2010-07-15 | |
| US61/364,698 | 2010-07-15 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013519849A Division JP5886283B2 (ja) | 2010-07-15 | 2011-07-15 | カドヘリン−１１のｅｃ１ドメインを標的とするヒト化抗体ならびに関連組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016116527A JP2016116527A (ja) | 2016-06-30 |
| JP2016116527A5 true JP2016116527A5 (ja) | 2016-09-08 |
| JP6223483B2 JP6223483B2 (ja) | 2017-11-01 |
Family
ID=44630044
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013519849A Active JP5886283B2 (ja) | 2010-07-15 | 2011-07-15 | カドヘリン−１１のｅｃ１ドメインを標的とするヒト化抗体ならびに関連組成物および方法 |
| JP2016023490A Active JP6223483B2 (ja) | 2010-07-15 | 2016-02-10 | カドヘリン−１１のｅｃ１ドメインを標的とするヒト化抗体ならびに関連組成物および方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013519849A Active JP5886283B2 (ja) | 2010-07-15 | 2011-07-15 | カドヘリン−１１のｅｃ１ドメインを標的とするヒト化抗体ならびに関連組成物および方法 |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US8940300B2 (ja) |
| EP (2) | EP2593128B1 (ja) |
| JP (2) | JP5886283B2 (ja) |
| KR (1) | KR101695056B1 (ja) |
| CN (2) | CN107090039A (ja) |
| AU (1) | AU2011279044B2 (ja) |
| BR (1) | BR112013001062A2 (ja) |
| CA (1) | CA2805112A1 (ja) |
| DK (1) | DK2593128T3 (ja) |
| ES (1) | ES2665317T3 (ja) |
| HR (1) | HRP20180563T1 (ja) |
| HU (1) | HUE038000T2 (ja) |
| IL (2) | IL224186A (ja) |
| LT (1) | LT2593128T (ja) |
| MX (1) | MX343376B (ja) |
| NO (1) | NO2593128T3 (ja) |
| PT (1) | PT2593128T (ja) |
| RS (1) | RS57215B1 (ja) |
| SG (1) | SG187097A1 (ja) |
| SI (1) | SI2593128T1 (ja) |
| WO (1) | WO2012009631A1 (ja) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0906492A2 (pt) * | 2008-01-11 | 2015-12-01 | Synovex Corp | antagonistas da caderina-11 e métodos para o tratamento de doenças inflamatórias das articulações |
| LT2593128T (lt) | 2010-07-15 | 2018-06-25 | Adheron Therapeutics, Inc. | Humanizuoti antikūnai, nukreipti į kadherino-11 ec1 domeną, ir susijusios kompozicijos ir būdai |
| PE20141568A1 (es) | 2011-10-28 | 2014-11-21 | Neotope Biosciences Ltd | Anticuerpos humanizados que reconocen la alfa-sinucleina |
| SG11201404321YA (en) | 2012-01-27 | 2014-08-28 | Neotope Biosciences Ltd | Humanized antibodies that recognize alpha-synuclein |
| US20150050240A1 (en) * | 2012-03-27 | 2015-02-19 | Novartis Ag | Treatment of fibrosis |
| UA118441C2 (uk) | 2012-10-08 | 2019-01-25 | Протена Біосаєнсиз Лімітед | Антитіло, що розпізнає альфа-синуклеїн |
| RU2015144026A (ru) * | 2013-03-15 | 2017-04-20 | Эббви Байотекнолоджи Лтд. | Антитела против cd25 и их применения |
| MX2015012563A (es) * | 2013-03-15 | 2016-10-26 | Abbvie Biotechnology Ltd | Anticuerpos anti-cd25 y sus usos. |
| US10513555B2 (en) | 2013-07-04 | 2019-12-24 | Prothena Biosciences Limited | Antibody formulations and methods |
| WO2016100301A1 (en) * | 2014-12-15 | 2016-06-23 | The Brigham And Women's Hospital, Inc. | Use of cadherin-11 antagonists to treat obesity-associated conditions and other metabolic disorders |
| AU2017206089B2 (en) * | 2016-01-09 | 2020-04-16 | Arbele Pty Ltd | Cadherin-17 specific antibodies and cytotoxic cells for cancer treatment |
| MX2021001268A (es) * | 2018-08-01 | 2021-09-08 | Imcheck Therapeutics Sas | Anticuerpos anti-btn3a y su uso en el tratamiento del cáncer o trastornos infecciosos. |
| CN113072633B (zh) * | 2021-04-21 | 2022-11-15 | 湖北医药学院 | Cdh11截短型变体及其应用 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4172124A (en) | 1978-04-28 | 1979-10-23 | The Wistar Institute | Method of producing tumor antibodies |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| EP0232262A4 (en) | 1985-08-15 | 1989-09-19 | Stauffer Chemical Co | MICROORGANISM PRODUCING TRYPTOPHANE. |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| EP1695978A1 (en) | 1990-06-11 | 2006-08-30 | Gilead Sciences, Inc. | Nucleic acid ligands |
| US5270163A (en) | 1990-06-11 | 1993-12-14 | University Research Corporation | Methods for identifying nucleic acid ligands |
| EP0464533B1 (de) | 1990-06-28 | 1998-07-29 | Hoechst Aktiengesellschaft | Fusionsproteine mit immunglobulinanteilen, ihre Herstellung und Verwendung |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5440021A (en) | 1991-03-29 | 1995-08-08 | Chuntharapai; Anan | Antibodies to human IL-8 type B receptor |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| EP0605522B1 (en) | 1991-09-23 | 1999-06-23 | Medical Research Council | Methods for the production of humanized antibodies |
| JP3560252B2 (ja) * | 1992-08-28 | 2004-09-02 | アベンティス ファーマ株式会社 | 骨関連カドヘリン様タンパク質およびその製造法 |
| DE614989T1 (de) | 1993-02-17 | 1995-09-28 | Morphosys Proteinoptimierung | Verfahren für in vivo Selektion von Ligandenbindende Proteine. |
| CU22584A1 (es) * | 1995-11-17 | 1999-11-03 | Centro Inmunologia Molecular | Composiciones farmacéuticas que contienen un anticuerpo monoclonal que reconoce el antígeno de diferenciación leucocitario humano cd6 y sus usos para el diagnóstico y tratamiento de la psoriasis |
| US6472367B1 (en) | 1998-05-05 | 2002-10-29 | Adherex Technologies, Inc. | Compounds and methods for modulating OB-cadherin mediated cell adhesion |
| US6680175B2 (en) | 1998-05-05 | 2004-01-20 | Adherex Technologies, Inc. | Methods for diagnosing and evaluating cancer |
| US7481999B2 (en) | 1998-05-05 | 2009-01-27 | Adherex Technologies, Inc. | Compounds and methods for modulating OB-cadherin-mediated function |
| WO1999057149A2 (en) * | 1998-05-05 | 1999-11-11 | Adherex Technologies, Inc. | Compounds and methods for modulating nonclassical cadherin-mediated functions |
| US6638911B1 (en) | 1998-05-05 | 2003-10-28 | Adherex Technologies Inc. | Compounds and methods for modulating desmosomal cadherin-mediated functions |
| US6787136B1 (en) | 1999-09-03 | 2004-09-07 | The Brigham And Women's Hospital, Inc. | Methods and compositions for treatment of inflammatory disease using cadherin-11 modulating agents |
| ATE479441T1 (de) | 1999-09-03 | 2010-09-15 | Brigham & Womens Hospital | Verfahren und zusammensetzungen zur behandlung von entzündungskrankheiten unter verwendung von cadherin-11-modulierenden agenzien |
| US20040110755A1 (en) | 2002-08-13 | 2004-06-10 | Boehringer Ingelheim Pharmaceuticals, Inc. | Combination therapy with p38 MAP kinase inhibitors and their pharmaceutical compositions |
| CA2506037A1 (en) | 2002-11-14 | 2004-06-10 | Adherex Technologies, Inc. | Compounds and methods for modulating desmosomal and atypical cadherin-mediated cell adhesion |
| EP1853255A4 (en) | 2005-02-22 | 2009-07-08 | Gemin X Pharmaceuticals Canada | METHODS FOR TREATING ARTHRITIS USING TRIHETEROCYCLIC COMPOUNDS |
| BRPI0906492A2 (pt) | 2008-01-11 | 2015-12-01 | Synovex Corp | antagonistas da caderina-11 e métodos para o tratamento de doenças inflamatórias das articulações |
| JP2011514318A (ja) * | 2008-02-11 | 2011-05-06 | ノバルティス アーゲー | カドヘリン１１（ｃｄｈ１１）アンタゴニストの使用方法 |
| LT2593128T (lt) | 2010-07-15 | 2018-06-25 | Adheron Therapeutics, Inc. | Humanizuoti antikūnai, nukreipti į kadherino-11 ec1 domeną, ir susijusios kompozicijos ir būdai |
-
2011
- 2011-07-15 LT LTEP11741717.0T patent/LT2593128T/lt unknown
- 2011-07-15 SG SG2013003454A patent/SG187097A1/en unknown
- 2011-07-15 CN CN201710140463.1A patent/CN107090039A/zh active Pending
- 2011-07-15 BR BR112013001062A patent/BR112013001062A2/pt not_active Application Discontinuation
- 2011-07-15 ES ES11741717.0T patent/ES2665317T3/es active Active
- 2011-07-15 JP JP2013519849A patent/JP5886283B2/ja active Active
- 2011-07-15 CN CN201180042808.0A patent/CN103153331B/zh active Active
- 2011-07-15 HU HUE11741717A patent/HUE038000T2/hu unknown
- 2011-07-15 MX MX2013000434A patent/MX343376B/es active IP Right Grant
- 2011-07-15 EP EP11741717.0A patent/EP2593128B1/en active Active
- 2011-07-15 RS RS20180419A patent/RS57215B1/sr unknown
- 2011-07-15 NO NO11741717A patent/NO2593128T3/no unknown
- 2011-07-15 PT PT117417170T patent/PT2593128T/pt unknown
- 2011-07-15 SI SI201131461T patent/SI2593128T1/en unknown
- 2011-07-15 DK DK11741717.0T patent/DK2593128T3/en active
- 2011-07-15 EP EP17203400.1A patent/EP3345925A3/en not_active Withdrawn
- 2011-07-15 AU AU2011279044A patent/AU2011279044B2/en not_active Ceased
- 2011-07-15 WO PCT/US2011/044172 patent/WO2012009631A1/en active Application Filing
- 2011-07-15 US US13/810,018 patent/US8940300B2/en active Active
- 2011-07-15 KR KR1020137003804A patent/KR101695056B1/ko active IP Right Grant
- 2011-07-15 CA CA2805112A patent/CA2805112A1/en not_active Abandoned
-
2013
- 2013-01-13 IL IL224186A patent/IL224186A/en active IP Right Grant
-
2015
- 2015-01-26 US US14/605,543 patent/US20150132305A1/en not_active Abandoned
-
2016
- 2016-01-26 IL IL243775A patent/IL243775A0/en unknown
- 2016-02-10 JP JP2016023490A patent/JP6223483B2/ja active Active
-
2018
- 2018-04-09 HR HRP20180563TT patent/HRP20180563T1/hr unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016116527A5 (ja) | ||
| JP2018127467A5 (ja) | ||
| CY1122840T1 (el) | Ανθρωποποιημενα ή χιμαιρικα αντισωματα cd3 | |
| JP2017176174A5 (ja) | ||
| EA201791093A1 (ru) | Антитела к cd47, способы и применение | |
| EP4276114A3 (en) | Cd20 binding single domain antibodies | |
| JP2019526543A5 (ja) | ||
| JP2014205674A5 (ja) | ||
| AU2018256498A1 (en) | Antibodies to amyloid beta | |
| JP2016502515A5 (ja) | ||
| MX2018000470A (es) | Moleculas de anticuerpo que se unen al grupo de diferenciacion 22 (cd22). | |
| JP2014534239A5 (ja) | ||
| PE20150002A1 (es) | Anticuerpos anti-fcrn | |
| EA201691824A1 (ru) | АНТИТЕЛА ПРОТИВ EGFRvIII И ИХ ПРИМЕНЕНИЯ | |
| JP2011157378A5 (ja) | ||
| JP2014509837A5 (ja) | ||
| JP2014237714A5 (ja) | ||
| EA201890320A1 (ru) | Молекулы антител, которые связывают cd79 | |
| EA201201227A1 (ru) | Бипаратопные а-бета-связывающие полипептиды | |
| JP2013241409A5 (ja) | ||
| WO2014152006A3 (en) | Anti-hepcidin antibodies and uses thereof | |
| PE20161032A1 (es) | Anticuerpos anti-tau(ps422) humanizados y metodos de utilizacion | |
| EA201790305A1 (ru) | КОМБИНИРОВАННАЯ ТЕРАПИЯ БОЛЕЗНИ АЛЬЦГЕЙМЕРА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ МОНОКЛОНАЛЬНЫХ АНТИТЕЛ К N3pGlu АБЕТА И ИНГИБИТОРА BACE | |
| JP2021504430A5 (ja) | ||
| JP2015530399A5 (ja) |